• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

Nubeqa Combo Positively Impacts HRQoL vs Placebo in Prostate Cancer Subgroup

by MM360 Staff | Jun 4, 2025 | Uncategorized

Source: CureToday articles Nubeqa and ADT treatment led to positive impacts on health-related quality of life vs placebo in metastatic hormone-sensitive prostate cancer. Read More

IDSA Guideline Recommendations: Treating Multi-Drug Resistant and Difficult to Treat Resistant P. aeruginosa

by MM360 Staff | Jun 4, 2025 | Myeloma News

Source: Pharmacy Times articles Infectious Disease Society of America guidance defines difficult-to-treat resistant Pseudomonas aeruginosa as resistance to all first-line agents. Read More

Rina-S Yields 50% Response Rate in Advanced Endometrial Cancer

by MM360 Staff | Jun 4, 2025 | Uncategorized

Source: CureToday articles Rina-S led to a 50% response rate, including two complete responses, in heavily pretreated advanced endometrial cancer, according to early trial findings. Read More

ASCO 2025: Adding Carboplatin Did Not Result in Statistically Significant Improvements in Patients With TNBC

by MM360 Staff | Jun 4, 2025 | Myeloma News

Source: Pharmacy Times articles New research finds that adding carboplatin to paclitaxel and adjuvant chemotherapy shows no significant survival benefits in triple-negative breast cancer (TNBC). Read More

Maximizing Your Pharmacy Fellowship Experience: Tips for Success

by MM360 Staff | Jun 4, 2025 | Myeloma News

Source: Pharmacy Times articles Establishing a strong foundation and effective networking strategies and pursuing opportunities are key. Read More
« Older Entries
Next Entries »

Recent Content

  • Ambulatory Pharmacy in Action: House Calls and Harm Reduction Clinics Expand the Reach of Care
  • Detailing the Potential Benefit of Intratumoral Therapies in Lung Cancer
  • Reimagining Pain Management: Pharmacists Urged to “Deconstruct the Cupcake”
  • Specialty Pharmacist Integration in Neurology Clinics: A Model for Enhanced Patient Care
  • Targeted Chemo Improves Survival in Early-Stage Lung Cancer
  • Utilizing AI in Prostate Cancer Care and Management
  • KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety
  • Rilonacept in Recurrent Pericarditis: Mechanism of Action, Patient Management, and Clinical Considerations
  • Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation
  • Op-Ed: Expand Patient Choice to Lower Medication Costs
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT